102 related articles for article (PubMed ID: 10517086)
1. [Histopathological effect and its predictors of neoadjuvant hormonal therapy by combined androgen blockade].
Ito T; Mamiya Y; Aizawa T; Akiyama A; Yamamoto S; Tsuzuki M; Yoshimasa O; Miki M; Furusato M
Nihon Hinyokika Gakkai Zasshi; 1999 Sep; 90(9):779-83. PubMed ID: 10517086
[TBL] [Abstract][Full Text] [Related]
2. PSA levels and the rate of positive surgical margins in radical prostatectomy specimens preceded by androgen blockade in clinical B2 (T2bNxMo) prostate cancer. The Lupron Depot Neoadjuvant Study Group.
McLeod DG; Johnson CF; Klein E; Peabody JO; Coffield S; Soloway M
Urology; 1997 Mar; 49(3A Suppl):70-3. PubMed ID: 9123740
[TBL] [Abstract][Full Text] [Related]
3. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer.
Gleave ME; Goldenberg SL; Jones EC; Bruchovsky N; Sullivan LD
J Urol; 1996 Jan; 155(1):213-9. PubMed ID: 7490838
[TBL] [Abstract][Full Text] [Related]
4. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
[TBL] [Abstract][Full Text] [Related]
5. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects.
Gleave ME; Goldenberg SL; Chin JL; Warner J; Saad F; Klotz LH; Jewett M; Kassabian V; Chetner M; Dupont C; Van Rensselaer S;
J Urol; 2001 Aug; 166(2):500-6; discussion 506-7. PubMed ID: 11458055
[TBL] [Abstract][Full Text] [Related]
6. The limited significance of a longer duration of neoadjuvant hormonal therapy prior to radical prostatectomy for high-risk prostate cancer in Japanese men.
Miyake H; Sakai I; Inoue TA; Hara I; Fujisawa M
Urol Int; 2006; 77(2):122-6. PubMed ID: 16888415
[TBL] [Abstract][Full Text] [Related]
7. Long-term neoadjuvant hormone therapy prior to radical prostatectomy: evaluation of risk for biochemical recurrence at 5-year follow-up.
Gleave ME; La Bianca SE; Goldenberg SL; Jones EC; Bruchovsky N; Sullivan LD
Urology; 2000 Aug; 56(2):289-94. PubMed ID: 10925096
[TBL] [Abstract][Full Text] [Related]
8. [Comparative study of the effect of complete prolonged neoadjuvant hormonal blockade versus standard hormonal blockade].
Lorente JA; Arango O; Bielsa O; Cortadellas R; Cañis D; Lloreta-Trull J; Gelabert-Mas A
Actas Urol Esp; 2003 Oct; 27(9):678-83. PubMed ID: 14626676
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer.
Prayer-Galetti T; Sacco E; Pagano F; Gardiman M; Cisternino A; Betto G; Sperandio P
BJU Int; 2007 Aug; 100(2):274-80. PubMed ID: 17355369
[TBL] [Abstract][Full Text] [Related]
10. Biological effect of neoadjuvant androgen-deprivation therapy assessed on specimens from radical prostatectomy: a systematic review.
Antonelli A; Palumbo C; Veccia A; Grisanti S; Triggiani L; Zamboni S; Furlan M; Simeone C; Magrini S; Berruti A
Minerva Urol Nefrol; 2018 Aug; 70(4):370-379. PubMed ID: 29392925
[TBL] [Abstract][Full Text] [Related]
11. Prostate specific antigen doubling time after radical prostatectomy: effect of neoadjuvant androgen deprivation therapy.
Rabbani F; Perrotti M; Bastar A; Fair WR
J Urol; 1999 Mar; 161(3):847-52. PubMed ID: 10022699
[TBL] [Abstract][Full Text] [Related]
12. [Effect of complete androgen block before radical prostatectomy for cancer of the prostate].
Gómez Veiga F; Lorenzo Patiño MJ; Díaz Bermúdez J; Duarte Novo J; Alvarez Castelo L; Chantada Abal V; Sánchez Rodríguez J; González Martín M
Arch Esp Urol; 1997 May; 50(4):355-63. PubMed ID: 9313044
[TBL] [Abstract][Full Text] [Related]
13. [Neoadjuvant hormonal therapy for prostate cancer].
Miyakita H
Nihon Rinsho; 2005 Feb; 63(2):309-13. PubMed ID: 15714984
[TBL] [Abstract][Full Text] [Related]
14. Effect of total androgen ablation on pathologic stage and resection limit status of prostate cancer. Initial results of the Italian PROSIT study.
Montironi R; Diamanti L; Santinelli A; Galetti-Prayer T; Zattoni F; Selvaggi FP; Pagano F; Bono AV
Pathol Res Pract; 1999; 195(4):201-8. PubMed ID: 10337657
[TBL] [Abstract][Full Text] [Related]
15. Predictors of pathological stage before neoadjuvant androgen withdrawal therapy and radical prostatectomy. The Canadian Urologic Oncology Group.
Rabbani F; Goldenberg SL; Klotz LH
J Urol; 1998 Mar; 159(3):925-8. PubMed ID: 9474184
[TBL] [Abstract][Full Text] [Related]
16. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
[TBL] [Abstract][Full Text] [Related]
17. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
Kupelian PA; Katcher J; Levin HS; Klein EA
Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
[TBL] [Abstract][Full Text] [Related]
18. Induction androgen deprivation therapy before radical prostatectomy for prostate cancer--initial results.
Abbas F; Kaplan M; Soloway MS
Br J Urol; 1996 Mar; 77(3):423-8. PubMed ID: 8814850
[TBL] [Abstract][Full Text] [Related]
19. Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma. The European Study Group on Neoadjuvant Treatment of Prostate Cancer.
Witjes WP; Schulman CC; Debruyne FM
Urology; 1997 Mar; 49(3A Suppl):65-9. PubMed ID: 9123739
[TBL] [Abstract][Full Text] [Related]
20. [Prognostic factors in patients with prostatic cancer treated with neoadjuvant hormonal therapy and radical prostatectomy].
Villavicencio Mavrich H; Chéchile Toniolo G; Salinas Duffo D; Muñoz Plaza J; Sorraca Ibáñez YJ
Arch Esp Urol; 1996 Oct; 49(8):797-806. PubMed ID: 9065276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
